Search Results - "BEHM, David J"

Targeting pulmonary capillary permeability to reduce lung congestion in heart failure: a randomized, controlled pilot trial by Stewart, Glenn M., Johnson, Bruce D., Sprecher, Dennis L., Reddy, Yogesh N.V., Obokata, Masaru, Goldsmith, Steven, Bart, Brad, Oughton, Anna, Fillmore, Christina, Behm, David J., Borlaug, Barry A.

“…Aims Lung congestion in patients with heart failure (HF) has traditionally been treated using interventions that reduce pulmonary capillary hydrostatic…”
Get full text

Effect of TRPV4 Antagonist GSK2798745 on Chlorine Gas-Induced Acute Lung Injury in a Swine Model by Vermillion, Meghan S, Saari, Nathan, Bray, Mathieu, Nelson, Andrew M, Bullard, Robert L, Rudolph, Karin, Gigliotti, Andrew P, Brendler, Jeffrey, Jantzi, Jacob, Kuehl, Philip J, McDonald, Jacob D, Burgert, Mark E, Weber, Waylon, Sucoloski, Scott, Behm, David J

“…As a regulator of alveolo-capillary barrier integrity, Transient Receptor Potential Vanilloid 4 (TRPV4) antagonism represents a promising strategy for reducing…”
Get full text

Systemic activation of the transient receptor potential vanilloid subtype 4 channel causes endothelial failure and circulatory collapse: Part 2 by Willette, Robert N, Bao, Weike, Nerurkar, Sandhya, Yue, Tian-Li, Doe, Chris P, Stankus, Gerald, Turner, Gregory H, Ju, Haisong, Thomas, Heath, Fishman, Cindy E, Sulpizio, Anthony, Behm, David J, Hoffman, Sandra, Lin, Zuojun, Lozinskaya, Irina, Casillas, Linda N, Lin, Min, Trout, Robert E Lee, Votta, Bartholomew J, Thorneloe, Kevin, Lashinger, Erin S R, Figueroa, David J, Marquis, Robert, Xu, Xiaoping

“…The transient receptor potential (TRP) vanilloid subtype 4 (V4) is a nonselective cation channel that exhibits polymodal activation and is expressed in the…”
Get more information

Discovery of GSK2193874: An Orally Active, Potent, and Selective Blocker of Transient Receptor Potential Vanilloid 4 by Cheung, Mui, Bao, Weike, Behm, David J, Brooks, Carl A, Bury, Michael J, Dowdell, Sarah E, Eidam, Hilary S, Fox, Ryan M, Goodman, Krista B, Holt, Dennis A, Lee, Dennis, Roethke, Theresa J, Willette, Robert N, Xu, Xiaoping, Ye, Guosen, Thorneloe, Kevin S

“…Transient Receptor Potential Vanilloid 4 (TRPV4) is a member of the Transient Receptor Potential (TRP) superfamily of cation channels. TRPV4 is expressed in…”
Get full text

Epoxyeicosatrienoic acids function as selective, endogenous antagonists of native thromboxane receptors: identification of a novel mechanism of vasodilation by Behm, David J, Ogbonna, Andrea, Wu, Charlene, Burns-Kurtis, Cynthia L, Douglas, Stephen A

“…Epoxy- and dihydroxy-eicosatrienoic acids (EETs and DHETs) are vasoactive cytochrome P450 metabolites of arachidonic acid. Interestingly, however, the…”
Get more information

Genetic and Pharmacological Manipulation of Urotensin II Ameliorate the Metabolic and Atherosclerosis Sequalae in Mice by You, Zhipeng, Genest, Jacques, Barrette, Pierre-Olivier, Hafiane, Anouar, Behm, David J, D’Orleans-Juste, Pedro, Schwertani, Adel Giaid

“…OBJECTIVE—Urotensin II (UII) is a potent vasoactive peptide that binds to the urotensin receptor–coupled receptor-14 (known as UT) and exerts a wide range of…”
Get full text

Adaptive study design to assess effect of TRPV4 inhibition in patients with chronic cough by Ludbrook, Valerie J., Hanrott, Kate E., Kreindler, James L., Marks-Konczalik, Joanna E., Bird, Nick P., Hewens, Debbie A., Beerahee, Misba, Behm, David J., Morice, Alyn, McGarvey, Lorcan, Parker, Sean M., Birring, Surinder S., Smith, Jaclyn

“…Objective Airway sensory nerves involved in the cough reflex are activated by adenosine triphosphate (ATP) agonism of P2X purinoceptor 3 (P2X3) receptors…”
Get full text

Novel Rho kinase inhibitors with anti-inflammatory and vasodilatory activities by Doe, Chris, Bentley, Ross, Behm, David J, Lafferty, Robert, Stavenger, Robert, Jung, David, Bamford, Mark, Panchal, Terry, Grygielko, Eugene, Wright, Lois L, Smith, Gary K, Chen, Zunxuan, Webb, Christine, Khandekar, Sanjay, Yi, Tracey, Kirkpatrick, Robert, Dul, Edward, Jolivette, Larry, Marino, Jr, Joseph P, Willette, Robert, Lee, Dennis, Hu, Erding

“…Increased Rho kinase (ROCK) activity contributes to smooth muscle contraction and regulates blood pressure homeostasis. We hypothesized that potent and…”
Get more information

Chronic Inhibition of Hypoxia-inducible Factor Prolyl 4-hydroxylase Improves Ventricular Performance, Remodeling, and Vascularity After Myocardial Infarction in the Rat by Bao, Weike, Qin, Pu, Needle, Saul, Erickson-Miller, Connie L, Duffy, Kevin J, Ariazi, Jennifer L, Zhao, Shufang, Olzinski, Alan R, Behm, David J, Teg Pipes, G C, Jucker, Beat M, Hu, Erding, Lepore, John J, Willette, Robert N

“…BACKGROUND:Hypoxia inducible factors (HIFs) are transcription factors that are regulated by HIF-prolyl 4-hydroxylases (PHDs) in response to changes in oxygen…”
Get full text

Potent, Selective and Orally Bioavailable Dihydropyrimidine Inhibitors of Rho Kinase (ROCK1) as Potential Therapeutic Agents for Cardiovascular Diseases by Sehon, Clark A, Wang, Gren Z, Viet, Andrew Q, Goodman, Krista B, Dowdell, Sarah E, Elkins, Patricia A, Semus, Simon F, Evans, Christopher, Jolivette, Larry J, Kirkpatrick, Robert B, Dul, Edward, Khandekar, Sanjay S, Yi, Tracey, Wright, Lois L, Smith, Gary K, Behm, David J, Bentley, Ross, Doe, Christopher P, Hu, Erding, Lee, Dennis

“…Recent studies using known Rho-associated kinase isoform 1 (ROCK1) inhibitors along with cellular and molecular biology data have revealed a pivotal role of…”
Get full text

Recent advances in TRPV4 agonists and antagonists by Lawhorn, Brian G., Brnardic, Edward J., Behm, David J.

“…[Display omitted] TRPV4 is a ubiquitously expressed, non-selective cation channel activated by a range of stimuli including hypotonicity, temperature, pH,…”
Get full text

Differential effects of p38 mitogen-activated protein kinase and cyclooxygenase 2 inhibitors in a model of cardiovascular disease by Willette, Robert N, Eybye, Marianne E, Olzinski, Alan R, Behm, David J, Aiyar, Nambi, Maniscalco, Kristeen, Bentley, Ross G, Coatney, Robert W, Zhao, Shufang, Westfall, Timothy D, Doe, Chris P

“…The evidence is compelling for a role of inflammation in cardiovascular diseases; however, the chronic use of anti-inflammatory drugs for these indications has…”
Get more information

Comparison of soluble guanylate cyclase stimulators and activators in models of cardiovascular disease associated with oxidative stress by Costell, Melissa H, Ancellin, Nicolas, Bernard, Roberta E, Zhao, Shufang, Upson, John J, Morgan, Lisa A, Maniscalco, Kristeen, Olzinski, Alan R, Ballard, Victoria L T, Herry, Kenny, Grondin, Pascal, Dodic, Nerina, Mirguet, Olivier, Bouillot, Anne, Gellibert, Francoise, Coatney, Robert W, Lepore, John J, Jucker, Beat M, Jolivette, Larry J, Willette, Robert N, Schnackenberg, Christine G, Behm, David J

“…Soluble guanylate cyclase (sGC), the primary mediator of nitric oxide (NO) bioactivity, exists as reduced (NO-sensitive) and oxidized (NO-insensitive) forms…”
Get full text

Effects of p38 MAPK Inhibitor on Angiotensin II-Dependent Hypertension, Organ Damage, and Superoxide Anion Production by Bao, Weike, Behm, David J, Nerurkar, Sandhya S, Ao, Zhaohui, Bentley, Ross, Mirabile, Rosanna C, Johns, Douglas G, Woods, Tina N, Doe, Christopher PA, Coatney, Robert W, Ohlstein, Jason F, Douglas, Stephen A, Willette, Robert N, Yue, Tian-Li

“…Angiotensin II (Ang II) activates p38 mitogen-activated protein kinase (p38 MAPK) and increases reactive oxygen species (ROS), but the nature of the…”
Get full text

Effects of Urotensin II Receptor Antagonist, GSK1440115, in Asthma by Portnoy, Alison, Kumar, Sanjay, Behm, David J, Mahar, Kelly M, Noble, Robert B, Throup, John P, Russ, Steven F

“…Urotensin II (U-II) is highly expressed in the human lung and has been implicated in regulating respiratory physiology in preclinical studies. Our objective…”
Get full text

p38 MAPK inhibitors ameliorate target organ damage in hypertension: Part 1. p38 MAPK-dependent endothelial dysfunction and hypertension by Ju, Haisong, Behm, David J, Nerurkar, Sandyha, Eybye, Marianne E, Haimbach, Robin E, Olzinski, Alan R, Douglas, Stephen A, Willette, Robert N

“…Numerous mediators, believed to play a role in endothelial dysfunction (e.g., neurohormones, cytokines, hypoxia, and stretch), have been shown to activate p38…”
Get more information

Evaluation of GSK2789917-induced TRPV4 inhibition in animal models of fluid induced lung injury by Bihari, Shailesh, Costell, Melissa H., Bouchier, Tara, Behm, David J., Burgert, Mark, Ye, Guosen, Bersten, Andrew D., Puukila, Stephanie, Cavallaro, Elena, Sprecher, Dennis L., Dixon, Dani-Louise

“…Administration of bolus intravenous fluids, common in pre-hospital and hospitalised patients, is associated with increased lung vascular permeability and…”
Get full text

Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge by Mole, Sarah, Harry, Anya, Fowler, Andy, Hotee, Sarah, Warburton, Joseph, Waite, Sarah, Beerahee, Misba, Behm, David J., Badorrek, Philipp, Müller, Meike, Faulenbach, Cornelia, Lazaar, Aili L., Hohlfeld, Jens M.

“…Acute Respiratory Distress Syndrome (ARDS) is associated with increased pulmonary-vascular permeability. In the lung, transient receptor potential vanilloid 4…”
Get full text

Toward improved myocardial maturity in an organ-on-chip platform with immature cardiac myocytes by Sheehy, Sean P, Grosberg, Anna, Qin, Pu, Behm, David J, Ferrier, John P, Eagleson, Mackenzie A, Nesmith, Alexander P, Krull, David, Falls, James G, Campbell, Patrick H, McCain, Megan L, Willette, Robert N, Hu, Erding, Parker, Kevin K

“…In vitro studies of cardiac physiology and drug response have traditionally been performed on individual isolated cardiomyocytes or isotropic monolayers of…”
Get full text

Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid‑4 (TRPV4) by Brnardic, Edward J, Ye, Guosen, Brooks, Carl, Donatelli, Carla, Barton, Linda, McAtee, Jeff, Sanchez, Robert M, Shu, Arthur, Erhard, Karl, Terrell, Lamont, Graczyk-Millbrandt, Grazyna, He, Yanan, Costell, Melissa H, Behm, David J, Roethke, Theresa, Stoy, Patrick, Holt, Dennis A, Lawhorn, Brian G

“…A novel series of pyrrolidine sulfonamide transient receptor potential vanilloid-4 (TRPV4) antagonists was developed by modification of a previously reported…”
Get full text